A Phase 1，Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ascendind Doses of BPI-28592 in Subjects With Advanced Solid Tumors
A Phase 1，Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ascendind Doses of BPI-28592 in Subjects With Advanced Solid Tumors
This is an open-labe Phase I study of BPI-28592 for the treatment of patients with solid tumors
Inclusion Criteria:
Exclusion Criteria:
shonco@sina.cn0571-86006922